SBL
DFTX

Sargent Bickham Lagudis’s Definium Therapeutics DFTX Stock Holding History

Sargent Bickham Lagudis’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$22 Hold
10
– – ﹤0.01% 1046
2022
Q3 		$0 Sell
10
-1
-9% -$10 ﹤0.01% 1075
2022
Q2 		$0 Hold
11
– – ﹤0.01% 1101
2022
Q1 		$0 Hold
11
– – ﹤0.01% 996
2021
Q4 		$0 Sell
11
-8
-42% -$255 ﹤0.01% 992
2021
Q3 		$1K Hold
19
– – ﹤0.01% 912
2021
Q2 		$1K Buy
+19
New +$997 ﹤0.01% 892

Other funds holding DFTX

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Sargent Bickham Lagudis's DFTX Position: Q4 2022 in Review

Sargent Bickham Lagudis held its Definium Therapeutics (DFTX) position steady in Q4 2022 at 10 shares worth $22. The position accounts for ﹤0.01% of the portfolio, ranked #1046.

Sargent Bickham Lagudis first reported a position in DFTX in Q2 2021 and has held it in 7 quarters since. The position peaked at $1K in Q3 2021. 104 funds tracked by Wall St. Rank hold DFTX as of Q4 2022.

  • Sargent Bickham Lagudis held 10 shares of Definium Therapeutics worth $22 as of Q4 2022.
  • Sargent Bickham Lagudis left its Definium Therapeutics share count unchanged in Q4 2022.
  • Definium Therapeutics made up ﹤0.01% of Sargent Bickham Lagudis's portfolio in Q4 2022, its #1046 holding.
  • Sargent Bickham Lagudis first reported a position in Definium Therapeutics in Q2 2021 and has held it in 7 quarters since.
  • Sargent Bickham Lagudis's Definium Therapeutics position peaked at $1K in Q3 2021.
  • 104 funds tracked by Wall St. Rank held Definium Therapeutics as of Q4 2022.

Based on Sargent Bickham Lagudis's 13F filing for Q4 2022, filed 23 Jan 2023.